Joel Habener
Joel Habener |
|---|
Joel Habener is a Professor of Medicine at Harvard Medical School.
Habener worked with Svetlana Mojsov on elucidating the role of incretin hormones such as Glucagon-like peptide-1 (GLP-1) and Glucagon-like peptide-2 (GLP-2). Habener received credit for the work on hormones when Mosjov was not credited.[1] Habener was awarded the 2020 Warren Alpert Foundation Prize along with Daniel Drucker and Jens Juul Holst.[2] He was elected to the National Academy of Sciences in 2020.[3] In 2021, he was awarded the Canada Gairdner International Award.[4] In 2023, he received the VinFuture Prize.[5] In 2024, he was awarded the Princess of Asturias Awards for Technical and Scientific Research,[6] the Tang Prize in the category of "Biopharmaceutical Science"[7] and also in 2024 the Lasker Award[8][9] for clinical research.
References
- ^ Molteni, Megan; Chen, Elaine (27 September 2023). "The Ozempic revolution is rooted in the work of Svetlana Mojsov, yet she's been edged out of the story". STAT. Retrieved 2023-10-09.
- ^ "Prize Recipients | Warren Alpert Foundation Prize". warrenalpert.org.
- ^ "2020 NAS Election". www.nasonline.org.
- ^ Canada Gairdner International Award 2021
- ^ Nhu, Quynh (21 December 2023). "Battery researchers win $3M Vietnamese awards". VnExpress.
- ^ Princess of Asturias Awards 2024
- ^ Tang Prize 2024
- ^ Albert Lasker Award for Clinical Research
- ^ Prashant Nair (19 September 2024). "QnAs with Svetlana Mojsov, Joel Habener, and Lotte Bjerre Knudsen: Winners of the 2024 Lasker~DeBakey Clinical Medical Research Award". Proceedings of the National Academy of Sciences of the United States of America. 121 (39). doi:10.1073/PNAS.2416868121. ISSN 0027-8424. Wikidata Q130375905.
| International | |
|---|---|
| National | |
| Other | |
   | This biographical article related to a physician in the United States is a stub. You can help Wikipedia by expanding it. |